
|Articles|April 1, 2022
Daily Medication Pearl: Ganciclovir Ophthalmic Gel
Author(s)Saro Arakelians, PharmD
Ganciclovir ophthalmic gel (Zirgan) is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
Advertisement
Medication Pearl of the Day: Ganciclovir ophthalmic gel (Zirgan)
Indication: Ganciclovir ophthalmic gel (Zirgan) is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).
Insight
- Dosing: The recommended dosing regimen for Zirgan is 1 drop in the affected eye, 5 times per day (approximately every 3 hours while awake) until the corneal ulcer heals, and then 1 drop 3 times per day for 7 days.
- Dosage forms: Zirgan contains 0.15% of ganciclovir in a sterile preserved topical ophthalmic gel.
- Adverse events: Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
- Mechanism of action: Zirgan contains the active ingredient, ganciclovir, which is a guanosine derivative that, upon phosphorylation, inhibits DNA replication by herpes simplex viruses. Ganciclovir is transformed by viral and cellular thymidine kinases to ganciclovir triphosphate, which works as an antiviral agent by inhibiting the synthesis of viral DNA in 2 ways: competitive inhibition of viral DNA-polymerase and direct incorporation into viral primer strand DNA, resulting in DNA chain termination and prevention of replication.
- Manufacturer: Bausch + Lomb
Sources
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Staging the Heart: NLA and EAS Reveal a New Era of Precision Lipidology and Imaging
2
Orforglipron Reduces Body Weight Up to 14% in Women at Every Stage of Menopause
3
Final CLL14 Analysis Confirms Durable Benefit With Fixed-Duration Venetoclax-Obinutuzumab in Frontline CLL
4
New Evidence Positions Finerenone as Foundational Therapy Across the CKD Spectrum
5


































































































































